GFAP and neurodegenerative disease: While GFAP release into the bloodstream is well-documented in acute brain injuries with transient blood-brain barrier disruptions, the mechanisms behind increased blood GFAP levels in neurodegenerative disease progression—especially when blood-brain barrier integrity is maintained—remain elusive.